Targeted therapy for advanced cancer based on tumor genetics
Part of Cancer clinical trials.
This trial tests different targeted therapies based on the unique genetic changes in your tumor. It is for people with advanced or metastatic cancer who have exhausted standard options and whose tumor has specific genetic markers matched to one of the study drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced or metastatic and not responding to standard treatments, or no standard treatment exists.
- Your tumor must have a specific genetic change (like a mutation in CDK4, CDK6, KRAS, BRAF, etc.) that matches one of the study's treatment groups.
- You must have had at least one prior treatment for your advanced cancer.
- You must be able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
This study uses your tumor’s genetic test results to help match you to the most suitable treatment when standard options have failed or don’t exist. It may help by targeting therapies based on specific gene changes found in your cancer.
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Hear when a new Malignant Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.